Andrew Joseph

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

An Alzheimer’s drug from Roche cleared a protein that’s a hallmark of the disease from patients’ brains, suggesting the drug shows promise.

Novartis had a strong third quarter, driven by growing sales of its psoriasis drug Cosentyx.

David Epstein, the Seagen CEO who helped sell the company to Pfizer in a blockbuster deal, is back to lead a new startup.

The high-profile venture firm @FlagshipPioneer now has a London outpost on the hunt for opportunities. @drjbajwa spoke with STAT.

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.

CVS Health has replaced Karen Lynch with David Joyner as CEO, part of an attempt to turn the struggling company around. 

Barney Graham, a former NIH vaccine developer, said U.S. agencies aren't coordinating the response to the bird flu outbreak among cows.

The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals in a deal worth $2.6 billion

The Nobel-winning scientists opened new doors in our understanding of the structure of proteins and came up with ways to create new proteins.